Registry of patient characteristics and outcomes in acute myeloid leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This registry study focuses on adult patients with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) and related neoplasms. It aims to collect comprehensive data on patient characteristics, biological disease profiles, and clinical outcomes over a maximum observation period of 10 years. The study will analyze genetic markers, treatment responses, and survival rates, while also assessing the impact of measurable residual disease on patient outcomes. Conducted across 80-90 sites in Germany and Austria, it seeks to enhance understanding of AML and improve treatment recommendations.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with suspected diagnosis of acute myeloid leukemia and related neoplasms, newly diagnosed or relapsed/refractory, classified according to the International Consensus Classification
* Age ≥ 18 years. There is no upper age limit.
* Signed written informed consent

Exclusion Criteria:

* Severe neurological or psychiatric disorder interfering with ability to give an informed consent
* No consent for registration, storage and processing of the individual patient and disease characteristics and course as well as information of the family physician about study participation
* No consent for biobanking of patient's biological specimens and performance of analyses on stored material.

Where it's running

• Medizinische Universität Graz
  Graz, Austria Recruiting
• Medizinische Universität Innsbruck
  Innsbruck, Austria Recruiting
• Krankenhaus der Elisabethinen Linz GmbH
  Linz, Austria Recruiting
• Kepler Universitätsklinikum GmbH
  Linz, Austria Recruiting
• Landeskrankenhaus Feldkirch
  Rankweil, Austria Recruiting
• Universitätsklinikum der PMU Landeskrankenhaus Salzburg
  Salzburg, Austria Recruiting

+44 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Hartmut Döhner, Prof. Dr.
• Email: hartmut.doehner@uniklinik-ulm.de
• Phone: 49-731-500-45501

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PBSS1113 with azacitidine for AML and higher-risk MDS

  This study tests PBSS1113 together with azacitidine to see if it is safe and may help people with AML or higher-risk MDS who are newly diagnosed and not fit for intense chemotherapy or who have relapsed/refractory disease.

  Recruiting Phase 1/2 Chaser Therapeutics, Inc. · Hangzhou, Zhejiang · NCT07761533

• Caris Chromoseq data collection for AML, MDS, and MPN

  This study tests how well the Caris Chromoseq assay helps categorize risk in patients with AML, MDS, or MPN compared with standard tests.

  Recruiting Caris Science, Inc. · Phoenix, Arizona · NCT07680868

• Venetoclax TDM in newly diagnosed AML: exposure and prognosis

  This study checks if measuring venetoclax levels and adjusting treatment helps people with newly diagnosed AML who are getting VEN-AZA.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou · NCT07670130

• CAR-T cells targeting CD33 and CLL1 for relapsed or refractory AML

  A one-arm early-stage trial tests whether a patient’s own engineered CAR-T cells (ICG415) can be safely given after conditioning chemotherapy to see if they can help adults with relapsed or refractory AML.

  Recruiting at 2 sites Phase 1 iCell Gene Therapeutics · Nanchang, Jiangxi and 1 other locations · NCT07668557

• Ropeginterferon Alfa-2b added to azacitidine in TP53-mutant MDS/AML

  This study tests whether adding ropeginterferon alfa-2b to azacitidine helps people with TP53-mutant MDS/AML, by finding an effective dose and looking for tumor response.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT07646821

• Ziftomenib for relapsed/refractory NPM1-mutated AML in Japanese adults

  This study will test whether ziftomenib can help adults with relapsed or refractory NPM1-mutated AML who have few other options.

  Recruiting at 15 sites Phase 2 Kyowa Kirin Co., Ltd. · Chiba and 19 other locations · NCT07623616

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.